Orion Group's Financial Statement documents for 2013 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi.
The official financial statement documents, which include the financial statements, the report of the Board of Directors and the auditor's report are available in Finnish at http://www.orion.fi/Orion/Yhtiokokoukset/Yhtiokokous-2014/.
Orion's Corporate Governance Statement for year 2013, adopted by the Board of Directors, is published as a separate report in Finnish and English on the Company's website at http://www.orion.fi/.
| Olli Huotari |
SVP, Corporate Functions
| Terhi Ormio |
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.